Clinical Trial Search

Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42

Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…

Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants

Primary: Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains…

Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number

Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer

Primary: Antibody Responses in Nasal Secretions to Influenza A/H1N1 and A/H3N2 at 14 Days After Intranasal Immunization. — 3; 3; 5; 0 Participants

Primary: Clinical Status of Participants on Day 7 — 1; 1; 2; 1 Participants — p=0.181

Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs — 40; 50 percentage of participants analyzed — p=0.046

Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants

Primary: Percentage of Participants Excreting Resistant Virus — 26.3; 35.3 percentage of participants — p=0.825

Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25

Primary: Percentage of Healthy Participants Reporting Mild-to-Moderate Influenza Disease (MMID) by Baseline A/Bethesda/MM2/H1N1 Hemagglutination Inhibition (HAI) Antibody…

Primary: Number of Participants With Any Adverse Event (AE), Drug-related AE, Grade 3 and Grade 4 AE, Grade 3 and 4 Drug-related AE , AE Leading to Discontinuation of Study Drug…

Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections

Primary: Number of Participants Having Adverse Events — 0; 1; 1; 1 Participants

Primary: Frequency Counts and Percentage of Subjects With Adverse Events — 6; 6; 1; 3 Participants

Primary: Oseltamivir Carboxylate AUC12 (Area Under the Curve). — 6; 1; 3; 0 participants

Primary: Change in Inflammatory Markers From Time Zero to 72 Hours — 2.4; 3.46; 0.91; 0.57 pg/ml — p=0.611

Primary: Number of Patients in Each of 6 Clinical Status Categories on Day 7 — 3; 2; 6; 11 Participants — p=.33

Primary: Percentage of Participants With Adverse Events — 80.4; 67.3; 74.5 percentage of participants

Primary: Time to Clinical Response (TTCR) in Participants With Confirmed Influenza — 5.87; 5.14; 5.63 Days — p=0.25

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events(SAEs, AEs Leading to Withdrawal, and Death — 1; 1; 3; 24 Partipants

Primary: Number of Participants With Any Adverse Event (AE) Considered to be Related to Study Treatment — 28; 5 Participants

Primary: Percentage of Participants With Adverse Events — 40.0; 47.3; 25.7; 29.1 percentage of participants

Primary: Number of PCR-confirmed Influenza Infections — 17; 3 Participants

Primary: Number and Percentage of Participants With Symptomatic Influenza Virus Infection After Challenge. — 4; 5; 28; 0 Participants

Primary: Assess the Safety and Tolerability of a Single IV Dose of VIS410 in Participants With Uncomplicated Influenza Infection — 57.1; 34.7; 45.9; 26.0 percentage of participants

Primary: Hospitalization — 26; 2 Participants

Primary: Safety - Serious Adverse Event — 0; 0; 0 SAEs